Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP
10 août 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it received scientific advice...
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
30 juil. 2020 08h47 HE
|
Hutchison China MediTech Limited
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs...
Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
28 juil. 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products...
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
28 juil. 2020 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an...
Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China
24 juil. 2020 02h00 HE
|
Hutchison China MediTech Limited
— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech...
Chi-Med to Announce 2020 Half-Year Financial Results
26 juin 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, June 26, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday,...
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
25 juin 2020 02h15 HE
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION –...
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
18 juin 2020 03h15 HE
|
Hutchison China MediTech Limited
LONDON, June 18, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track...
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
09 juin 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, June 09, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited...
Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review
04 juin 2020 02h00 HE
|
Hutchison China MediTech Limited
LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of...